ACIP Work Groups

Print
Related Pages

ACIP uses subgroups of the Committee, known as Work Groups, to review relevant published and unpublished data and develop recommendation options for presentation to the ACIP. The goal of ACIP Work Groups is to increase the effectiveness of ACIP.

ACIP Work Groups are responsible for collection, analysis, and preparation of information for presentation, discussion, deliberation, and vote by the ACIP in an open public forum. Work Groups review specific topics in detail and clarify issues in a way that helps ACIP voting members make informed and efficient decisions, with the best and most current information available.

The following Work Groups are currently active (click on the name of each Work Group for more information): (Updated 5/13/2022)

Chikungunya Vaccines

  • Work Group Purpose: The Chikungunya Vaccines Work Group reviews and evaluates data on chikungunya disease, epidemiology, and vaccines and develops policy options for ACIP’s consideration.
  • Topics under discussion by the Work Group:
    • Use of chikungunya vaccines in U.S. persons at risk of chikungunya, including those who travel abroad, laboratory workers, and residents of U.S. territories and states with, or at risk of, transmission.
  • Work Group activities:
    • Review information on chikungunya disease, including outcomes.
    • Review data on chikungunya epidemiology and burden among U.S. residents, including travelers and persons living in areas at risk for local transmission.
    • Review data on safety, immunogenicity, and effectiveness of chikungunya vaccines.
    • Provide evidence-based recommendation options for ACIP.
    • Identify areas in need of further research for informing potential future vaccine recommendations.
    • Publish chikungunya vaccine MMWR Recommendations and Reports document.
  • Work Group Lead: Susan Hills
  • Work Group Chair: Wilbur Chen
Top of Page

Combined Child/Adolescent and Adult Immunization Schedule

  • Work Group Purpose: The Combined Child/Adolescent and Adult Immunization Schedule Work Group edits and maintains the child/adolescent and adult immunization schedule documents. The child/adolescent immunization schedule summarizes the ACIP vaccination recommendations for persons 18 years of age and younger, and the adult immunization schedule summarizes the ACIP vaccination recommendations for persons 19 years of age and older.
  • Topics under discussion by the Work Group: The products of this work group do not establish new vaccine recommendations; the work group documents reflect existing ACIP recommendations.
  • Work Group activities:
    • Publication of the child/adolescent and adult immunization schedules
  • Work Group Co-Leads: Patricia Wodi (acting)
  • Work Group Chair: Sybil Cineas
Top of Page

COVID-19 Vaccines

  • Work group purpose: The COVID-19 Vaccines Work Group reviews available data to inform COVID-19 vaccine policy, including recommendations for use of COVID-19 vaccines in the US population.
  • Topics under discussion by the Work Group:
    • Use of COVID-19 vaccines in the U.S. population
  • Work group activities:
    • Review safety, effectiveness, and immunogenicity data for COVID-19 vaccines, particularly in vaccine candidates authorized, approved, or in clinical trials in the US.
    • Review the epidemiology of COVID-19 disease.
    • Assess the benefit-risk balance for use of COVID-19 vaccines.
    • Identify areas where additional data are needed to inform COVID-19 vaccine recommendations.
    • Develop COVID-19 vaccine policy options.
  • Work Group Co-Leads: Megan Wallace and Lakshmi Panagiotakopoulos
  • Work Group Chair: Matthew Daley
Top of Page

Influenza Vaccines

  • Work Group Purpose: The Influenza Vaccine Work Group discusses the annual seasonal influenza vaccination recommendations and develops policy options for ACIP’s consideration. The Work Group reviews data and literature related to influenza vaccine efficacy, effectiveness, and safety.  Data concerning new licensures and licensure changes are also discussed.
  • Topics under discussion by the Work Group:
    • Assessment of specific influenza vaccines in specific populations (e.g., based upon age, risk factors for severe illness, susceptibility to adverse events)
    • Timing of vaccination
    • Vaccination during pregnancy
    • Evidence assessment and policy development for new vaccines
    • Effectiveness and safety of different influenza vaccines relative to one another
  • Work Group activities:
    • Ongoing discussions of vaccine effectiveness (VE)
    • Ongoing discussions of vaccine safety
    • Discussion of new licensures and licensure changes as relevant
  • Work Group Lead: Lisa Grohskopf
  • Work Group Chair: Jamie Loehr
Top of Page

Meningococcal/Hib Vaccines

  • Work Group Purpose: The Meningococcal Vaccines Work Group discusses meningococcal vaccine recommendations and develops policy options for ACIP’s consideration. In addition, the meningococcal vaccines work group has been evaluating the Haemophilus influenzae type b (Hib) component of Vaxelis® and developing updated policy options for ACIP’s consideration.
  • Topics under discussion by the Work Group:
    • Meningococcal vaccine topics:
      • The adolescent meningococcal vaccine schedule is being revisited to ensure vaccines are administered at a time to optimize protection for higher risk ages (e.g., re-consideration of the 11-12 year-old dose for MenACWY, higher meningitis B risk during first year of college) and reflect implementation considerations (e.g., routine vs. risk-based vs. shared clinical decision-making recommendations, harmonization with existing adolescent platform).
      • Guidance for use of GSK’s pentavalent meningococcal vaccine will be developed.  It is anticipated that this vaccine will be licensed as a 2-dose series (doses separated by 6 months) for the prevention of Neisseria meningitidis infections in persons ages 10 through 25 years.
    • Hib vaccine topic: Should Vaxelis (DTaP-IPV-Hib-HepB) be included with PedvaxHIB in the preferential recommendation for AI/AN infants?
  • Work Group activities:
    • Meningococcal vaccine activities:
      • Review the epidemiology of invasive meningococcal disease in the U.S., including burden in adolescents (including race/ethnicity) and breakthrough infections
      • Review immunogenicity and safety clinical trial data for GSK’s pentavalent vaccine
      • Perform economic analyses (including burden of disease averted by vaccination)
      • Develop draft policy recommendations based on grading of recommendations, assessment, development and evaluation (GRADE) and the evidence to recommendations (EtR) framework
    • Hib vaccine activities:
      • Review the epidemiology of invasive Hib disease in American Indian/Alaska Native populations and evidence supporting the existing preferential recommendation for PedvaxHib
      • Review clinical trial data on post-dose 1 immunogenicity of Vaxelis vs. PedvaxHib
      • Develop draft policy recommendations based on grading of recommendations, assessment, development and evaluation (GRADE) and the evidence to recommendations (EtR) framework
  • Lead: Sarah Schillie and Jennifer Collins
  • Work Group Chair: Jamie Loehr
Top of Page

Pneumococcal Vaccines

  • Work Group Purpose: Each year in the United States, pneumococcal disease causes thousands of infections, such as meningitis, bloodstream infections, pneumonia, and ear infections. The Pneumococcal Vaccines Work Group:
    • Reviews current data on pneumococcal disease epidemiology;
    • Reviews current data on pneumococcal vaccines and assesses the strength of the evidence;
    • Assesses cost-effectiveness and public health impact of new and current vaccine policy options; and
    • Develops revised or updated policy options for pneumococcal vaccines as needed.
  • Topics under discussion by the Work Group:
    • Use of new pneumococcal conjugate vaccines in U.S. adults and children.
  • Work Group activities:
    • Reviews new evidence on pneumococcal disease epidemiology and pneumococcal vaccine coverage in the United States.
    • Reviews new evidence on pneumococcal vaccines that are currently recommended in the United States.
    • Reviews evidence on new pneumococcal vaccines in advanced stages of development.
    • Summarize evidence relevant to the policy questions considered by the ACIP using Evidence to Recommendations framework and GRADE.
    • Update MMWR Policy Note and MMWR Recommendation and Report, as needed.
  • Work Group Lead: Miwako Kobayashi
  • Work Group Chair: Jamie Loehr
Top of Page

Respiratory Syncytial Virus Vaccines – Pediatric/Maternal

  • Work Group Purpose: Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions. In 2023, RSV vaccines and monoclonal antibodies were recommended by CDC for the first time, and additional candidate vaccines and long-acting monoclonal antibodies are being developed. Target populations for whom these products are intended include infants and young children, pregnant people, and older adults.
    This Work Group will focus on products intended for infants, young children, and pregnant people. Another Work Group will focus on products for older adults.
  • Topics under discussion by the Work Group:
    • Use of RSV vaccine(s) in pregnant people and long-acting monoclonal antibody products in infants and young children.
  • Work Group activities: Consider recommendation options for use of RSV vaccines and long-acting monoclonal antibodies targeting prevention of RSV disease in children <18 years-old
    • Review the epidemiology and burden of RSV disease in children and pregnant people
    • Review efficacy/effectiveness, immunogenicity, safety, and cost-effectiveness of RSV vaccine(s) administered to pregnant people and long-acting monoclonal antibody products in infants and young children.
    • Provide evidence-based recommendation options regarding use of RSV vaccine(s) in pregnant people and long-acting monoclonal antibody products in infants and young children.
    • Identify areas in need of further research for informing potential future vaccine and long-acting monoclonal antibody recommendations
  • Work Group Lead: Jefferson Jones and Katherine Fleming-Dutra
  • Work Group Chair: Sarah Long
Top of Page

Respiratory Syncytial Virus Vaccines – Adult

  • Work Group Purpose: Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions. RSV vaccine development has progressed in the past decade, with the first RSV vaccines for adults licensed and recommended in 2023. Target populations for whom these products are intended include infants and young children, pregnant people, older adults, and adults with chronic or immunocompromising medical conditions.
    This Work Group will consider policy questions related to vaccination to prevent severe RSV disease in adults. The separate pediatric/maternal Work Group will consider policy topics related to vaccination of infants, young children, and pregnant people.
  • Topics under discussion by the Work Group:
    • FDA- approved RSV vaccines and other immunization products pending licensure.
    • Target populations for RSV vaccination recommendations, defined by age and risk factors for severe RSV disease.
    • Appropriateness and timing of RSV revaccination.
  • Work Group activities: Consider recommendation options for the use of RSV vaccines in older adults, adults with immune compromise, and adults with other risk factors for severe RSV disease:
    • Review the epidemiology and burden of RSV disease in older adults and adults with adults with risk factors for severe RSV disease.
    • Review efficacy, immunogenicity, safety, and cost-effectiveness of RSV vaccine(s) in older adults and adults with risk factors for severe RSV disease.
    • Provide options for evidence-based recommendations regarding use of RSV vaccine(s) in older adults and adults with risk factors for severe RSV disease.
    • Identify areas in need of further research and review data on experience with current RSV vaccine recommendations to inform updates to RSV vaccine policy.
  • Work Group Lead: Michael Melgar and Amadea Britton
  • Work Group Chair: Camille Kotton
Top of Page